Author

S. A. Boswell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

P. K. Sorger· 3 shared C. E. Mills· 2 shared R. A. Everley· 2 shared A. A. Chen· 1 shared A. C. Palmer· 1 shared A. E. Ringel· 1 shared A. J. Nirmal· 1 shared A. R. Erickson· 1 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. K. Sorger

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes

L. M. Doherty, C. E. Mills, S. A. Boswell, X. Liu, C. T. Hoyt, B. M. Gyori, S. J. Buhrlage, P. K. Sorger

This study integrates multi-omics data to identify DUB functions and therapeutic targets, revealing key enzymes like USP14, UCHL5, and USP7 with potential in cancer therapy.

bioRxiv · Aug 6, 2021Cancer Biology

Micro-region transcriptomics of fixed human tissue using Pick-Seq

Z. Maliga, A. J. Nirmal, N. G. Ericson, S. A. Boswell, L. U'Ren, R. Podyminogin, J. Chow, Y.-A. Chen, A. A. Chen, D. M. Weinstock, C. G. Lian, G. F. Murphy, E. P. Kaldjian, S. Santagata, P. K. Sorger

Pick-Seq enables deep spatial transcriptomic profiling of fixed human tissue, revealing transcriptional differences in tumor invasion, proliferation, and immuno-editing.

bioRxiv · Mar 18, 2021 · PreprintCancer Biology

Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming

H. Wang, R. P. Sheehan, A. C. Palmer, R. A. Everley, S. A. Boswell, N. Ron-Harel, A. E. Ringel, K. M. Holton, C. A. Jacobson, A. R. Erickson, L. Maliszewski, M. C. Haigis, P. K. Sorger

Cell Systems · May 1, 2019Peer-reviewedPharmacology & Toxicology

Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity

M. Hafner, C. E. Mills, K. Subramanian, C. Chen, M. Chung, S. A. Boswell, R. A. Everley, C. Liu, C. S. Walmsley, D. Juric, P. Sorger

This study compares the mechanisms of three FDA-approved CDK4/6 inhibitors and finds significant differences in their transcriptional, proteomic, and cellular effects, suggesting potential for differential clinical use.

bioRxiv · Mar 19, 2019Cancer Biology

Tubulin mRNA stability is sensitive to change in microtubule dynamics caused by multiple physiological and toxic cues

I. Gasic, S. A. Boswell, T. J. Mitchison

The paper shows that tubulin mRNA stability changes with microtubule dynamics, responding to various physiological and toxic cues, and proposes a new genomic approach to study microtubule regulation.

bioRxiv · Jan 29, 2019Cell Biology